Corvus Pharmaceuticals, Inc is starting a trial of CPI-006 in hospitalized Covid-19 patients.

 

This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.

The clinical trial started in February 25, 2021 and will continue throughout January 30, 2022.

To compare the proportion of participants alive and respiratory failure free of CPI-006 plus SOC versus placebo plus SOC will be primary outcome measure. Proportion of participants who are alive and free from respiratory deterioration measured by the 8-point ordinal scale.

For more details: https://ichgcp.net/clinical-trials-registry/NCT04734873.

Clinical Research News

Upcoming Clinical Trials